Hiddo J L Heerspink Selected Research

Creatinine

10/2022	Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial.
5/2022	The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet.
4/2022	Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions.
3/2022	The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists.
1/2022	Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial.
1/2022	Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia.
1/2022	Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers.
1/2022	Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD.
12/2021	The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial.
11/2021	Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiddo J L Heerspink Research Topics

Disease

136	Type 2 Diabetes Mellitus (MODY) 10/2022 - 01/2016
73	Chronic Renal Insufficiency 10/2022 - 04/2016
66	Albuminuria 06/2022 - 01/2016
42	Heart Failure 10/2022 - 09/2016
36	Diabetic Nephropathies (Diabetic Nephropathy) 05/2022 - 01/2016
29	Kidney Diseases (Kidney Disease) 10/2022 - 01/2016
28	Renal Insufficiency (Renal Failure) 04/2022 - 01/2018
19	Chronic Kidney Failure (Chronic Renal Failure) 01/2022 - 04/2016
18	Body Weight (Weight, Body) 01/2022 - 01/2017
16	Cardiovascular Diseases (Cardiovascular Disease) 10/2022 - 04/2016
8	Inflammation (Inflammations) 10/2022 - 01/2018
8	Proteinuria 11/2021 - 12/2017
7	Disease Progression 06/2022 - 01/2016
7	Myocardial Infarction 01/2022 - 09/2016
7	Diabetes Mellitus 01/2022 - 01/2016
5	Infections 04/2022 - 09/2016
5	Acute Kidney Injury (Acute Renal Failure) 01/2022 - 09/2016
5	Hypertension (High Blood Pressure) 01/2022 - 12/2017
5	Stroke (Strokes) 01/2022 - 09/2016
4	Hyperkalemia 10/2022 - 01/2020
4	Obesity 01/2022 - 10/2016
3	Overweight 01/2022 - 01/2021
3	Neoplasms (Cancer) 01/2021 - 01/2020
3	IGA Glomerulonephritis (IGA Nephropathy) 01/2021 - 01/2021
3	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2020 - 01/2016
2	COVID-19 04/2022 - 01/2022
2	Edema (Dropsy) 12/2021 - 09/2017
2	Anemia 08/2021 - 12/2020
2	Glomerulonephritis 01/2021 - 01/2021
2	Ketosis 01/2021 - 01/2021
2	Acute Coronary Syndrome 01/2020 - 11/2018
2	Hypotension (Low Blood Pressure) 01/2020 - 01/2020

Drug/Important Bio-Agent (IBA)

55	CreatinineIBA 10/2022 - 04/2016
51	dapagliflozinIBA 08/2022 - 05/2017
46	Glucose (Dextrose)FDA LinkGeneric 10/2022 - 10/2017
45	SodiumIBA 10/2022 - 09/2016
44	AlbuminsIBA 10/2022 - 04/2016
40	Sodium-Glucose Transporter 2 InhibitorsIBA 10/2022 - 09/2016
31	CanagliflozinIBA 10/2022 - 01/2017
26	Biomarkers (Surrogate Marker)IBA 05/2022 - 01/2016
23	Sodium-Glucose Transport ProteinsIBA 10/2022 - 09/2016
20	SymportersIBA 01/2022 - 10/2017
19	Pharmaceutical PreparationsIBA 11/2021 - 11/2016
15	AtrasentanIBA 01/2022 - 01/2017
11	empagliflozinIBA 06/2022 - 09/2016
9	DiureticsIBA 10/2022 - 09/2017
9	Hemoglobins (Hemoglobin)IBA 04/2022 - 09/2016
7	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2022 - 01/2019
6	PotassiumIBA 10/2022 - 01/2020
6	Endothelin Receptor AntagonistsIBA 01/2022 - 11/2019
6	Proteins (Proteins, Gene)FDA Link 08/2021 - 01/2019
5	Mineralocorticoid Receptor AntagonistsIBA 10/2022 - 01/2018
5	Uric Acid (Urate)IBA 01/2022 - 01/2018
5	Angiotensin Receptor AntagonistsIBA 11/2019 - 01/2016
4	Spironolactone (Aldactone)FDA LinkGeneric 03/2022 - 01/2018
4	Glucagon-Like Peptide-1 ReceptorIBA 01/2022 - 11/2018
4	HDL LipoproteinsIBA 01/2022 - 01/2020
4	HDL CholesterolIBA 01/2022 - 01/2020
4	Losartan (Cozaar)FDA LinkGeneric 01/2021 - 01/2016
4	Exenatide (Byetta)FDA Link 01/2021 - 10/2019
4	CholesterolIBA 01/2020 - 01/2017
4	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 11/2019 - 04/2016
3	finerenoneIBA 06/2022 - 10/2020
3	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2022 - 10/2018
3	Liraglutide FDA Link 01/2022 - 11/2020
3	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2022 - 01/2018
3	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2022 - 01/2021
3	DiamondIBA 01/2022 - 01/2020
3	LDL CholesterolIBA 01/2022 - 01/2021
3	omega-Chloroacetophenone (Mace)IBA 01/2022 - 01/2018
3	Lipoproteins (Lipoprotein)IBA 01/2022 - 01/2020
3	LinagliptinIBA 09/2021 - 01/2017
3	Serum AlbuminIBA 08/2021 - 01/2020
3	Biological ProductsIBA 02/2019 - 01/2019
2	Hormones (Hormone)IBA 05/2022 - 01/2019
2	Eplerenone (Inspra)FDA LinkGeneric 03/2022 - 01/2022
2	Type I Tumor Necrosis Factor ReceptorsIBA 01/2022 - 01/2019
2	MineralsIBA 01/2022 - 01/2019
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2022 - 01/2022
2	Insulin (Novolin)FDA Link 01/2022 - 01/2022
2	LDL Lipoproteins (beta Lipoproteins)IBA 01/2022 - 01/2021
2	Dipeptidyl-Peptidase IV InhibitorsIBA 09/2021 - 01/2020
2	Immunoglobulin A (IgA)IBA 01/2021 - 01/2021
2	Peptides (Polypeptides)IBA 01/2021 - 01/2018
2	Gliclazide (Diamicron)IBA 01/2021 - 01/2020
2	2- benzylidene- 3- (cyclohexylamino)- 2,3- dihydro- 1H- inden- 1- oneIBA 01/2021 - 01/2019
2	Phosphates (Orthophosphate)IBA 01/2020 - 01/2019
2	glimepiride (Amarel)FDA LinkGeneric 01/2020 - 01/2017
2	Atorvastatin (Lipitor)FDA Link 12/2019 - 10/2019
2	Rosuvastatin Calcium (Crestor)FDA Link 12/2019 - 10/2019
2	Endothelin A ReceptorIBA 11/2019 - 01/2018
2	bardoxolone methylIBA 10/2019 - 01/2018
2	Metformin (Glucophage)FDA LinkGeneric 10/2019 - 01/2017
2	IncretinsIBA 01/2019 - 01/2019

Therapy/Procedure

37	Therapeutics 06/2022 - 01/2016
6	Precision Medicine 05/2022 - 10/2018
4	Renal Replacement Therapy (Therapies, Renal Replacement) 04/2022 - 01/2018
3	Transplantation 01/2022 - 01/2019
3	Kidney Transplantation 11/2019 - 01/2018
2	Secondary Prevention 01/2021 - 01/2019